Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMGN Amgen

Trading 05-02 14:35:50 EDT

277.87

+0.50

+0.18%

High278.52	Low274.92	Vol1.30M
Open277.69	D1 Closing277.37	Amplitude1.30%
Mkt Cap149.04B	Tradable Cap148.61B	Total Shares536.38M
T/O360.34M	T/O Rate0.24%	Tradable Shares534.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"Amgen","latestPrice":277.87,"timestamp":1714674949368,"preClose":277.37,"halted":0,"volume":1302768,"delay":0,"floatShares":534807507,"shares":536375548,"eps":12.49,"marketStatus":"Trading","change":0.5,"latestTime":"05-02 14:35:50 EDT","open":277.69,"high":278.515,"low":274.915,"amount":360343023.264,"amplitude":0.012979,"askPrice":277.87,"askSize":123,"bidPrice":277.73,"bidSize":20,"shortable":3,"etf":0,"ttmEps":12.49,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1714680000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":277.37,"dividendRate":0.030662,"preHourTrading":{"tag":"盘前","latestPrice":279,"preClose":277.37,"latestTime":"09:21 EDT","volume":993,"amount":276457.83324,"timestamp":1714656100788},"postHourTrading":{"tag":"盘后","latestPrice":277.54,"preClose":277.37,"latestTime":"19:54 EDT","volume":130120,"amount":36091944.9182,"timestamp":1714607674613},"volumeRatio":0.708888,"optionData":{"bulkOrders":[{"symbol":"AMGN","call":false,"expireDate":1718942400000,"strike":"235.0","timestamp":1714660015819,"price":1.09,"volume":2250,"amount":245250,"type":"-"}]}},"requestUrl":"/m/hq/s/AMGN/","defaultTab":"news","newsList":[{"id":"2432493301","title":"BUZZ-PREVIEW: Amgen slips ahead of Q1 earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2432493301","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432493301?lang=en_us&edition=fundamental","pubTime":"2024-05-03 01:38","pubTimestamp":1714671517,"startTime":"0","endTime":"0","summary":"** Amgen    shares down 0.8% at $275.05 ahead of Q1 results due after the closing bell    ** The biotech company is expected to post EPS of $3.87 on revenue $7.44 bln, per LSEG data, vs yr-ago results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432675120","title":"Options Volatility and Implied Earnings Moves Today, May 02, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432675120","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432675120?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:05","pubTimestamp":1714647942,"startTime":"0","endTime":"0","summary":"Today, several major companies are expected to report earnings: Amgen (AMGN), Apple (AAPL), Conocophillips (COP), Mercadolibre (MELI), Block (SQ), ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/options-volatility-and-implied-earnings-moves-today-may-02-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/options-volatility-and-implied-earnings-moves-today-may-02-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432867310","title":"Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2432867310","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432867310?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:52","pubTimestamp":1714647171,"startTime":"0","endTime":"0","summary":"U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38576979/nasdaq-s-p-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not","is_publish_highlight":false,"gpt_icon":1},{"id":"2432596186","title":"Notable earnings after Thursday's close","url":"https://stock-news.laohu8.com/highlight/detail?id=2432596186","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432596186?lang=en_us&edition=fundamental","pubTime":"2024-05-02 05:35","pubTimestamp":1714599320,"startTime":"0","endTime":"0","summary":"Major earnings expected after the bell on Thursday include:  Apple  Block  Amgen  Coinbase Global  DraftKings   Other earnings slated for release after Thursday's close include:   AAON, ACA, ACCO, AEE, AES, ALG, ALTR, AMH, ARDX, ASND, ASUR, ATGE, ATRO, AXTI, BBAI, BECN, BFAM, BILL, BJRI, BKNG, BOOM, CABO, CDXS, CERS, CIVI, CLAR, CLFD, COHU, CPT, CRDF, CSTL, CTHR, CTO, CTRA, CTRE, DLB, DLR, DMRC, DRH, DVA, EB, ED, EOG, EVC, EXPE, FDP, FDUS, FIVN, FND, FOXF, FRT, FTNT, GAU, GDDY, GEVO, GLPG, GSIT, HOLX, HTGC, HUN, ILMN, IR, IRTC, JYNT, KRC, KURA, KWR, LASR, LFVN, LMAT, LNT, LOCO, LXRX, LYV, MATW, MELI, MNST, MP, MRIN, MSI, MTZ, MX, NR, OFS, OHI, OLED, OPEN, OSPN, OTEX, OUT, PBYI, PCTY, PLMR, POST, PTVE, PXD, RARE, REG, REZI, RGA, RKT, RMAX, SAND, SEM, SES, SIMO, SM, SPT, SPXC, STEM, SWN, TDW, TNDM, TPIC, OTCPK:TRRSF, TRUP, TWOU, TWST, TXRH, UDMY, UMH, UPLD, VIAV, VIR, VREX, VRRM, WK, WSC, WTRG, WW, X, XHR, XPOF, ZEUS, ZYME  For Seeking Alpha's full earnings season calendar, click here.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097359-notable-earnings-after-thursdays-close","is_publish_highlight":false,"gpt_icon":1},{"id":"2432165561","title":"Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2432165561","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432165561?lang=en_us&edition=fundamental","pubTime":"2024-05-02 05:07","pubTimestamp":1714597664,"startTime":"0","endTime":"0","summary":"Amgen Inc. shares have dropped some 20% since reaching an all-time high in February due to a below-consensus outlook and patent concerns.The company's four pillars of growth are General Medicine, Oncology, Inflammatory Diseases, and Rare Diseases.Amgen's obesity candidate MariTide has the potential to become its biggest revenue producer, with Phase 2 results expected in late 2024.Time to buy the dip?","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688193-amgen-stock-recent-weakness-is-not-a-buying-opportunity-yet","is_publish_highlight":false,"gpt_icon":0},{"id":"2432363583","title":"Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can","url":"https://stock-news.laohu8.com/highlight/detail?id=2432363583","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2432363583?lang=en_us&edition=fundamental","pubTime":"2024-05-02 03:00","pubTimestamp":1714590028,"startTime":"0","endTime":"0","summary":"Uncover the vulnerabilities of these Dow stocks to sell, with potential declines due to cash flow issues, pricing pressures and flat sales.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/ticking-time-bombs-3-dow-stocks-to-dump-while-you-still-can/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432507941","title":"Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season","url":"https://stock-news.laohu8.com/highlight/detail?id=2432507941","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432507941?lang=en_us&edition=fundamental","pubTime":"2024-05-01 23:46","pubTimestamp":1714578403,"startTime":"0","endTime":"0","summary":"Amgen (NASDAQ:AMGN) is scheduled to announce Q1 earnings results on Thursday, May 2nd, after market close. Analysts estimate a profit of $3.91 per share (-1.8% Y/Y) on revenue of $7.45B (+22.1% Y/Y). ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097477-amgen-q1-earnings-preview-obesity-treatment-updates-to-be-the-focus-this-season","is_publish_highlight":false,"gpt_icon":0},{"id":"2432506729","title":"CytomX surges on upcoming data for Amgen-partnered cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2432506729","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432506729?lang=en_us&edition=fundamental","pubTime":"2024-05-01 22:42","pubTimestamp":1714574576,"startTime":"0","endTime":"0","summary":"Shares of CytomX Therapeutics  climbed in the morning hours on Wednesday after the cancer drug developer fast-tracked an early-stage readout from its experimental bispecific antibody, CX-904, developed in partnership with Amgen . The San Francisco, California-based biotech said that alongside its Q1 2024 financials expected on May 8 after the market close, the company would also release initial Phase 1a data for CX-904 from an ongoing dose escalation study.  CX-904 is currently undergoing a Phase 1 trial in certain patients with solid tumors, and in March, the company said its early Phase 1a results would be available in H2 2024. In 2017, Amgen  partnered with CytomX  to jointly develop and commercialize T-cell-engaging, EGFR-targeting bispecific therapeutics such as CX-904.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug","is_publish_highlight":false,"gpt_icon":0},{"id":"2432527227","title":"BRIEF-Amgen Highlights New COPD, Asthma And Vasculitis Research At ATS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432527227","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432527227?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:34","pubTimestamp":1714563240,"startTime":"0","endTime":"0","summary":"May 1 (Reuters) - Amgen Inc   :   * AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024Source text for Eikon:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432738315","title":"Amgen investors await weight-loss drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2432738315","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432738315?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:04","pubTimestamp":1714561454,"startTime":"0","endTime":"0","summary":" - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday.Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June.MariTide is \"hitting these targets in a really different and unique way ... medically this could translate into better efficacy and better durability,\" Bradner said.\"Weekly injections with weekly symptoms is not for every patient, and we're hopeful that the dose and schedule of MariTide will be much less frequent,\" Bradner said, referring to side effects of the medicines.Shares of Amgen have fallen about 15% since early February, when full results of its 49-person MariTide study were published in a medical journal, including details on trial drop outs and high rates of nausea.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QLiX5h8mdhnx9uvgl1EMVg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/20e8dda07e1dfcc9fffcd6cd5b0443bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QLiX5h8mdhnx9uvgl1EMVg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/20e8dda07e1dfcc9fffcd6cd5b0443bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-investors-await-weight-loss-110414936.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432738795","title":"AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432738795","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2432738795?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:00","pubTimestamp":1714561200,"startTime":"0","endTime":"0","summary":"Findings From Tezspire  Phase 2a COURSE COPD Study. Phase 1 Study on AMG104/AZD8630  in Moderate to Severe Asthma. New TAVNEOS  Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement. THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen  today announced the presentation of new respiratory data at the American Thoracic Society 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.\"We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with Tezspire and our Phase 1 investigational study of asthma with AMG104/AZD8630, an inhaled anti-TSLP therapy,\" said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. \"Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options.\". Other rese","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-highlights-copd-asthma-vasculitis-110000272.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-highlights-copd-asthma-vasculitis-110000272.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432221855","title":"Arcutis Biotherapeutics: Betting Big On Zoryve","url":"https://stock-news.laohu8.com/highlight/detail?id=2432221855","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432221855?lang=en_us&edition=fundamental","pubTime":"2024-05-01 18:57","pubTimestamp":1714561022,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics is a biopharmaceutical company focused on developing therapies for dermatological diseases.The company has received FDA approval for its drug Zoryve and is expecting further la","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1808965219/image_1808965219.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1808965219/image_1808965219.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687904-arcutis-biotherapeutics-betting-big-on-zoryve","is_publish_highlight":false,"gpt_icon":0},{"id":"2432391655","title":"Amgen Inc    expected to post earnings of $3.87 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432391655","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432391655?lang=en_us&edition=fundamental","pubTime":"2024-05-01 05:29","pubTimestamp":1714512576,"startTime":"0","endTime":"0","summary":"* Amgen Inc     is expected to show a rise in quarterly revenue when it reports  results on May 2 for the period ending March 31 2024   * The Thousand Oaks California-based  company is expected to rep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432830754","title":"Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2432830754","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432830754?lang=en_us&edition=fundamental","pubTime":"2024-05-01 01:54","pubTimestamp":1714499699,"startTime":"0","endTime":"0","summary":"Generic and biosimilar manufacturerSandoz AG reachedan agreement on Tuesday withAmgenInc to resolve all patent litigation related to its U.S. denosumab biosimilars.Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyoston May 31, 2025, or earlier under certain circumstances.“The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said.Sandoz received FDA approval for the first and only denosumab biosimilars, Jubbontiand Wyost, on March 5, 2024.Jubbontiand Wyostare interchangeable with and approved by the FDA for all indications of reference medicines Proliaand Xgeva.They have the same dosage form, route of administration, dosing regimen, and presentation as the respective reference medicines.Denosumab is a human monoclonal antibody used for osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Patent infringement proceedings were initially filed by Am","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lxovMpKTGm_MjA9TeipkfQ--~B/aD01Njk7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/97ffc6eacef153c0476c4bc5f97b6036","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lxovMpKTGm_MjA9TeipkfQ--~B/aD01Njk7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/97ffc6eacef153c0476c4bc5f97b6036"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandoz-settles-patent-dispute-amgen-175459814.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432053893","title":"Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?","url":"https://stock-news.laohu8.com/highlight/detail?id=2432053893","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432053893?lang=en_us&edition=fundamental","pubTime":"2024-04-30 23:20","pubTimestamp":1714490400,"startTime":"0","endTime":"0","summary":"The first-quarter 2024 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.With many pharma and biotech bigwigs having already reported results, the earnings picture has been mixed. Although nearly all of these companies have beat bottom-line estimates, some have missed out on the top line. Last week, AbbVie and AstraZeneca reported impressive first-quarter results, with their earnings and sales beating estimates. While AstraZeneca’s top line was driven by increased demand for its key oncology and rare disease drugs, AbbVie’s sales grew on the back of strong demand for immunology and oncology products.Moderna has an impeccable earnings track record to date. Its earnings beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 79.46%. In the last reported quarter, MRNA’s earnings beat estimat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-drug-biotech-stocks-beat-152000802.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431266913","title":"Dow Drops 150 Points On Losses For Caterpillar, Amgen Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2431266913","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2431266913?lang=en_us&edition=fundamental","pubTime":"2024-04-30 21:45","pubTimestamp":1714484700,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.The Dow Jones Industrial Average is falling Tuesday morning with shares of Caterpillar and Amgen delivering the stiffest headwinds for the blue-chip average. The Dow  was most recently trading 153 points lower , as shares of Caterpillar  and Amgen  are contributing to the index's intraday decline. Caterpillar's shares have fallen $5.26  while those of Amgen are down $3.92, or 1.4%, combining for a roughly 60-point drag on the Dow. Also contributing significantly to the decline are Verizon , Salesforce , and McDonald's . A $1 move in any of the benchmark's 30 components equates to a 6.57-point swing.Data source: Dow Jones Market Data, FactSet. Data compiled April 30, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431312804","title":"Options Watchlist: 10 Stocks Showing High IV Percentile","url":"https://stock-news.laohu8.com/highlight/detail?id=2431312804","media":"Barchart","top":-1,"share":"https://ttm.financial/m/news/2431312804?lang=en_us&edition=fundamental","pubTime":"2024-04-30 19:00","pubTimestamp":1714474802,"startTime":"0","endTime":"0","summary":"One of the most common metrics used when trading options is the Implied Volatility Percentile.IV Percentile is a measure of implied volatility where current implied volatility is compared to the past ","market":"us","thumbnail":"https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Options/shutterstock_318403496.jpg","type":0,"news_type":0,"thumbnails":["https://media.barchart.com/contributors-admin/common-images/images/Stocks%2C%20Markets%2C%20%26%20Global%20Economy/Options/shutterstock_318403496.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.barchart.com/story/news/25839151/options-watchlist-10-stocks-showing-high-iv-percentile","is_publish_highlight":false,"gpt_icon":0},{"id":"2431036662","title":"Sandoz, Amgen reach agreement resolving patent litigation over biosimilars","url":"https://stock-news.laohu8.com/highlight/detail?id=2431036662","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431036662?lang=en_us&edition=fundamental","pubTime":"2024-04-30 15:32","pubTimestamp":1714462368,"startTime":"0","endTime":"0","summary":"Swiss drugmaker Sandoz  on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen  resolving all patent disputes between the two companies relating to the Food and Drug Administration-approved Sandoz denosumab biosimilars. The settlement clears the path to bring both denosumab biosimilars, Jubbonti and Wyost, to the U.S. market on May 31, 2025, or earlier under certain circumstances, Sandoz  said in a statement. Sandoz received FDA approval for the first denosumab biosimilars to treat skeletal-related events and osteoporosis on March 5, 2024. Sandoz  further added that the terms of the agreement will not impact the company's previously disclosed 2024 guidance.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation","is_publish_highlight":false,"gpt_icon":0},{"id":"2431358031","title":"Sandoz reaches agreement with Amgen over patent dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2431358031","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2431358031?lang=en_us&edition=fundamental","pubTime":"2024-04-30 13:28","pubTimestamp":1714454880,"startTime":"0","endTime":"0","summary":"ZURICH, April 30 (Reuters) - Swiss generic and biosimilar manufacturer Sandoz    said on Tuesday it had reached an agreement with U.S. drugmaker Amgen    resolving all patent litigation related to its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431392828","title":"AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2431392828","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2431392828?lang=en_us&edition=fundamental","pubTime":"2024-04-30 04:00","pubTimestamp":1714420800,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., April 29, 2024 /PRNewswire/ -- Amgen  today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. Th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-announces-webcast-2024-first-200000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-announces-webcast-2024-first-200000655.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.1454},{"period":"6month","weight":0.0278},{"period":"1year","weight":0.1754},{"period":"ytd","weight":-0.037}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.","yearOnYearQuotes":[{"month":1,"riseRate":0.634146,"avgChangeRate":0.032606},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.003118},{"month":3,"riseRate":0.512195,"avgChangeRate":0.019417},{"month":4,"riseRate":0.463415,"avgChangeRate":-0.001307},{"month":5,"riseRate":0.536585,"avgChangeRate":0.022463},{"month":6,"riseRate":0.5,"avgChangeRate":0.004307},{"month":7,"riseRate":0.756098,"avgChangeRate":0.052175},{"month":8,"riseRate":0.609756,"avgChangeRate":0.00518},{"month":9,"riseRate":0.536585,"avgChangeRate":0.003724},{"month":10,"riseRate":0.536585,"avgChangeRate":0.021341},{"month":11,"riseRate":0.634146,"avgChangeRate":0.022436},{"month":12,"riseRate":0.658537,"avgChangeRate":0.050861}],"exchange":"NASDAQ","name":"Amgen","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amgen,AMGN,Amgen股票,Amgen股票老虎,Amgen股票老虎国际,Amgen行情,Amgen股票行情,Amgen股价,Amgen股市,Amgen股票价格,Amgen股票交易,Amgen股票购买,Amgen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction